These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33632165)

  • 1. Initiation of hepatitis C treatment in two rural Rwandan districts: a mobile clinic approach.
    Kamali I; Barnhart DA; Nyirahabihirwe F; de la Paix Gakuru J; Uwase M; Nizeyumuremyi E; Walker S; Mazimpaka C; de Dieu Gatete J; Makuza JD; Serumondo J; Kateera F; d'Amour Ndahimana J
    BMC Infect Dis; 2021 Feb; 21(1):220. PubMed ID: 33632165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time to complete hepatitis C cascade of care among patients identified during mass screening campaigns in rural Rwanda: a retrospective cohort study.
    Kamali I; Shumbusho F; Barnhart DA; Nyirahabihirwe F; Gakuru JP; Dusingizimana W; Nizeyumuremyi E; Habinshuti P; Walker S; Makuza JD; Serumondo J; Nshogoza Rwibasira G; Ndahimana JD
    BMC Infect Dis; 2022 Mar; 22(1):272. PubMed ID: 35313817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators.
    Serumondo J; Penkunas MJ; Niyikora J; Ngwije A; Kiromera A; Musabeyezu E; Umutesi J; Umuraza S; Musengimana G; Nsanzimana S
    BMC Public Health; 2020 Jun; 20(1):946. PubMed ID: 32546216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of hepatitis B and C infection and linkage to care among patients with Non-Communicable Diseases in three rural Rwandan districts: a retrospective cross-sectional study.
    Musafiri T; Kamali I; Kayihura C; de la Paix Gakuru J; Nyirahabihirwe F; Nizeyimana E; Kandamage P; Habinshuti P; Sekagarura R; Makuza JD; Karema N; Serumondo J; Ntakirutimana T; Ndahimana JD; Barnhart DA
    BMC Infect Dis; 2024 Feb; 24(1):247. PubMed ID: 38388353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knowledge among patients with Hepatitis C initiating on direct-acting antiviral treatment in rural Rwanda: A prospective cohort study.
    Barnhart DA; Kamali I; Nyirahabihirwe F; Mugabo C; Gakuru JP; Uwase M; Nizeyumuremyi E; Musafiri T; Gatete JD; Makuza JD; Kateera F; Hedt-Gauthier B; Ndahimana JD
    Glob Health Action; 2021 Jan; 14(1):1953250. PubMed ID: 34347569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Cascade of Care for Hepatitis C Treatment in Rwanda: A Retrospective Cohort Study of the 2017-2019 Mass Screening and Treatment Campaign.
    Nisingizwe MP; Makuza JD; Janjua NZ; Bansback N; Hedt-Gauthier B; Serumondo J; Remera E; Law MR
    Viruses; 2023 Feb; 15(3):. PubMed ID: 36992370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost evaluation of reproductive and primary health care mobile service delivery for women in two rural districts in South Africa.
    Schnippel K; Lince-Deroche N; van den Handel T; Molefi S; Bruce S; Firnhaber C
    PLoS One; 2015; 10(3):e0119236. PubMed ID: 25751528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A real-world observational study of drug utilization and clinical outcomes of direct-acting antivirals and interferon therapy for hepatitis C treatment in Taiwan.
    Chen JH; Wu PN; Huang SC; Hsu PJ; Hsu JC
    Curr Med Res Opin; 2021 Feb; 37(2):245-252. PubMed ID: 33251875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges of transferring rural adults with chronic HCV infection for further HCV RNA confirmation and free DAAs treatment: a success story of the interdisciplinary collaboration approach.
    Li W; Chang TS; Chang SZ; Chen CH; Chen MY
    BMC Infect Dis; 2020 Oct; 20(1):737. PubMed ID: 33028228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of Direct-acting Antivirals for the Treatment of Chronic Hepatitis C in Rwanda: A Retrospective Study.
    Nsanzimana S; Penkunas MJ; Liu CY; Sebuhoro D; Ngwije A; Remera E; Umutesi J; Ntirenganya C; Mugeni SD; Serumondo J
    Clin Infect Dis; 2021 Nov; 73(9):e3300-e3307. PubMed ID: 32505127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world treatment for chronic hepatitis C infection in Germany: Analyses from drug prescription data, 2010-2015.
    Zimmermann R; Kollan C; Ingiliz P; Mauss S; Schmidt D; Bremer V
    J Hepatol; 2017 Jul; 67(1):15-22. PubMed ID: 28189752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
    Kim KA; Chung W; Choi HY; Ki M; Jang ES; Jeong SH
    Liver Int; 2019 Jan; 39(1):60-69. PubMed ID: 29998565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.
    Nishibatake Kinoshita M; Minami T; Tateishi R; Wake T; Nakagomi R; Fujiwara N; Sato M; Uchino K; Enooku K; Nakagawa H; Asaoka Y; Shiina S; Koike K
    J Hepatol; 2019 Jan; 70(1):78-86. PubMed ID: 30336183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals.
    Nitulescu R; Young J; Saeed S; Cooper C; Cox J; Martel-Laferriere V; Hull M; Walmsley S; Tyndall M; Wong A; Klein MB;
    Int J Drug Policy; 2019 Mar; 65():41-49. PubMed ID: 30594080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting.
    Dhiman RK; Grover GS; Premkumar M; Taneja S; Duseja A; Arora S; Rathi S; Satsangi S; Roy A;
    J Hepatol; 2019 Dec; 71(6):1076-1085. PubMed ID: 31325468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uptake of hepatitis C direct-acting antiviral treatment in China: a retrospective study from 2017 to 2021.
    Du X; Mi J; Cheng H; Song Y; Li Y; Sun J; Chan P; Chen Z; Luo S
    Infect Dis Poverty; 2023 Mar; 12(1):28. PubMed ID: 36978198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cost analysis of the diagnosis and treatment of malaria at public health facilities and communities in three districts in Rwanda.
    Masimbi O; Schurer JM; Rafferty E; Ndahimana JA; Amuguni JH
    Malar J; 2022 May; 21(1):150. PubMed ID: 35570297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving.
    Chhatwal J; He T; Hur C; Lopez-Olivo MA
    Clin Gastroenterol Hepatol; 2017 Jun; 15(6):827-837.e8. PubMed ID: 27650326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
    World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.